30 Nov 2016 16:35
PRESS RELEASE
FOR IMMEDIATE RELEASE
Award of options by Chief Executive Officer over personally owned shares to
Chief Financial Officer and General Counsel
London UK 30 November 2016: Ergomed plc ("Ergomed" or the "Company", LSE: ERGO), a pharmaceutical services and drug development company, today announces that Dr Miroslav Reljanović, founder and Chief Executive Officer of Ergomed, has granted options over 250,000 ordinary shares from his personal holding to Stephen Stamp, Chief Financal Officer and Sanja Jurić, General Counsel as follows:
Name | No. of options | Exercise Price | Vesting | Resulting interest in options | Current shareholding in the Company |
Stephen Stamp | 100,000 | £0.01 | 50% 11 January 2017 50% 11 January 2018 | 500,000 | 200,000 |
Sanja Jurić | 150,000 | £0.01 | 50% 30 November 2016 50% 30 November 2017 | 300,000 | NIL |
The 250,000 ordinary shares over which Dr Reljanović has granted options will remain in his personal holding until exercise. Dr Reljanović is interested in 17,632,237 ordinary shares of the Company, representing 43.53% of the issued share capital.
- ENDS -
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 503205 |
Miroslav Reljanovic (Chief Executive Officer) | |
Stephen Stamp (Chief Financial Officer) | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) | |
James Black (Joint Broker) | |
Stifel Nicolaus Europe Limited | Tel: +44 (0) 20 7710 7600 |
Jonathan Senior (Joint Broker) | |
FTI Consulting - for UK enquiries | Tel: +44 (0) 20 3727 1000 |
Simon Conway / Mo Noonan | |
MC Services AG - for Continental European enquiries | Tel: +49 (0) 211 52925222 |
Anne Hennecke |
About Ergomed
Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.
Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings. For further information, visit: http://ergomedplc.com.